Tesamorelin vs sermorelin vs cjc-1295: how these growth hormone peptides differ in FDA status, dosing, and research use, plus safety notes for US buyers.
Tesamorelin, sermorelin, and CJC-1295 are all growth hormone-releasing hormone (GHRH) analogs, but they are not interchangeable. Tesamorelin is the only one with FDA approval for a specific human condition, sermorelin is a short-acting peptide now available mainly through compounding, and CJC-1295 is sold almost entirely as a research chemical. The differences that matter most are half-life, regulatory status, and the strength of the evidence behind each one.
What Each Peptide Is
All three peptides signal the pituitary gland to release growth hormone, but each molecule is built differently and stays active for a different amount of time.
Tesamorelin
Tesamorelin is a synthetic 44-amino-acid GHRH analog sold under the brand name Egrifta. The FDA approved it to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is injected subcutaneously once daily and is not approved for general weight loss or anti-aging use.
Sermorelin
Sermorelin is a truncated 29-amino-acid piece of GHRH, often written as GHRH(1-29). It was once marketed as Geref for evaluating and treating growth hormone deficiency in children. The brand was discontinued in the United States in 2008, and today sermorelin is mainly prepared by compounding pharmacies.
CJC-1295
CJC-1295 is a modified GHRH analog designed to resist enzymatic breakdown. Two versions show up in research settings: CJC-1295 with DAC, which binds to albumin and stays active for days, and CJC-1295 without DAC, which clears in about half an hour.
Tesamorelin vs Sermorelin vs CJC-1295 at a Glance
The table below summarizes the differences that come up most often when people compare these three peptides.
| Feature | Tesamorelin | Sermorelin | CJC-1295 |
|---|---|---|---|
| Class | GHRH analog (44 amino acids) | GHRH fragment (1-29) | Modified GHRH analog |
| Half-life | About 26 to 38 minutes | About 10 to 20 minutes | Roughly 30 minutes without DAC; 6 to 8 days with DAC |
| FDA approval | Approved for HIV-associated lipodystrophy | No current US brand; previously approved | None |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
| Doses used in labeling or research | 1.4 mg or 2 mg once daily | About 100 to 300 mcg per dose | About 1 to 2 mcg/kg with DAC; about 100 mcg without DAC |
| Growth hormone pattern | Sustained daily elevation | Short pulses | Pulses without DAC; sustained with DAC |
Those amounts come from FDA labeling or published research protocols. They are not recommendations, and compounded or research-grade products are not required to match them.
FDA Status and Legal Availability in the US
Tesamorelin is the only one of the three peptides with FDA approval for human use in the United States. Egrifta WR is available by prescription for a narrow indication, which means it is not a general-purpose fat-loss drug.
Sermorelin is no longer marketed as an FDA-approved brand-name medicine in the US. It can still be compounded with a prescription in many states, which is one reason it remains popular in wellness clinics.
CJC-1295 is not FDA-approved for human use in the United States. It is sold as a research chemical, and the FDA has taken steps to restrict compounding of several GHRH-related peptides. Vials labeled "for research use only" are not reviewed for purity, sterility, or actual peptide content.
Half-Life, Dosing, and the DAC Question
Half-life drives almost every practical difference between these peptides. Sermorelin and CJC-1295 without DAC leave the bloodstream quickly, so they produce short bursts of growth hormone release that resemble natural pulses.
The comparison of cjc-1295 no dac vs sermorelin comes down to how long each peptide survives and how closely a protocol mimics the body's own rhythm. CJC-1295 without DAC is somewhat more stable, while sermorelin is the shorter of the two.
CJC-1295 with DAC behaves very differently. Its albumin-binding design keeps it active for roughly six to eight days, which produces a steady elevation of growth hormone instead of a pulse.
Timing matters in every protocol. For research use, the best time to take cjc 1295 ipamorelin is usually discussed in relation to natural GH pulses, which peak during deep sleep in the first hours after falling asleep.
How These Peptides Are Used Together
People searching cjc-1295 ipamorelin vs tesamorelin are usually weighing a stacked research protocol against a single FDA-approved drug. That comparison is uneven, because only tesamorelin has human trial data and an approved label behind it.
Some clinics promote a sermorelin cjc 1295 combination, but no published head-to-head trial compares that blend against either peptide used alone.
Related compounds get pulled into the same conversations. Questions such as bpc-157 vs cjc 1295 belong to a different category, because BPC-157 is studied for tissue repair rather than growth hormone signaling. AOD-9604, another frequently mentioned peptide, is an HGH fragment studied for fat metabolism and does not act on the pituitary the way GHRH analogs do.
Side Effects and Safety Considerations
Reported side effects for GHRH analogs include injection site reactions, flushing, headache, and tingling or numbness in the hands and feet. Tesamorelin's label also notes increases in IGF-1, fluid retention, and joint pain.
Elevated growth hormone and IGF-1 for months at a time carries real risks, including insulin resistance, swelling, and carpal tunnel symptoms. These peptides are generally not considered appropriate for people who are pregnant or who have active cancer.
Key Takeaways
- Tesamorelin is the only one of the three peptides with FDA approval for human use in the United States.
- Sermorelin was discontinued as a US brand drug in 2008 and is now mainly a compounded product.
- CJC-1295 is not FDA-approved for human use and is sold as a research chemical.
- CJC-1295 with DAC stays active for about a week, while CJC-1295 without DAC clears in roughly 30 minutes.
- None of these peptides is approved for general weight loss, and none should replace medical care.
Anyone considering these compounds should discuss the risks with a licensed healthcare professional and be cautious about unverified suppliers, because research chemical vials are not regulated the way prescription drugs are.
Frequently Asked Questions
Is tesamorelin or CJC-1295 stronger?
Neither peptide is simply "stronger" than the other, because they release growth hormone in different patterns. CJC-1295 with DAC keeps growth hormone elevated for about a week, while tesamorelin produces a daily rise and is the only one with an FDA-approved label. Only tesamorelin has been studied in large human trials for a specific medical condition.
Does sermorelin still require a prescription in the US?
Sermorelin is no longer sold as an FDA-approved brand-name drug in the United States, but compounded sermorelin still requires a prescription from a licensed clinician. It cannot be legally purchased over the counter. Compounded products are not FDA-approved, so potency and purity can vary by pharmacy.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) modification lets CJC-1295 bind to albumin in the blood, extending its half-life from roughly 30 minutes to about six to eight days. CJC-1295 without DAC, sometimes called Mod GRF 1-29, produces short growth hormone pulses instead of a sustained elevation. Neither version is FDA-approved for human use in the United States.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.